Kite, A Gilead Company

Quick facts

Phase 3 pipeline

• KITE-753 · Oncology
  KITE-753 is a CAR-T cell therapy that redirects a patient's own T cells to recognize and kill cancer cells expressing a specific tumor antigen.
• Platinum-containing Salvage Chemotherapy · Oncology
  Platinum-containing chemotherapy agents work by forming DNA adducts that cross-link DNA strands, preventing replication and transcription, thereby inducing cancer cell death.

Phase 2 pipeline

• Anitocabtagene autleucel · Oncology
  Anitocabtagene autleucel is a chimeric antigen receptor (CAR) T-cell therapy that targets the B-cell maturation antigen (BCMA) on multiple myeloma cells.
• KITE-197
• KITE-363
• KTE-X19

Phase 1 pipeline

• KTE-C19

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Kite, A Gilead Company portfolio CI brief
• Kite, A Gilead Company pipeline updates RSS